<DOC>
	<DOC>NCT00120757</DOC>
	<brief_summary>Osteopenia and osteoporosis are being described more frequently in people with HIV infection. This study will test the efficacy of alendronate in comparison with a placebo after 2 years, in people with primary osteoporosis. People will receive the recommended adequate intake of calcium and vitamin D.</brief_summary>
	<brief_title>Efficacy of Alendronate Versus Placebo in the Treatment of HIV-associated Osteoporosis (ANRS120)</brief_title>
	<detailed_description>The purposes of this trial are: - To study the efficacy of alendronate in HIV-associated osteoporosis - To measure the prevalence of osteoporosis in HIV patients and to detect risk factors in a large cohort of HIV patients from the screening phase</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Alendronate</mesh_term>
	<criteria>Nonpregnant Non menopausal women Total femur BMD below 2.5 SD (T score) or lumbar spine BMD below 2.5 SD (T score) or BMD below 1 associated with a vertebral osteoporotic fracture (diminution of vertebral height over 20%) HIV infection known for at least 5 years CD4 cell count over 50/mm3 Karnofsky score over or equal to 70 Written informed consent. Osteoporosis resulting from a cause other than HIV: vitamin D deficiency (in that case, after receiving highdose calcium and vitamin D for 1 month, patients will be randomized without a new screening), renal failure, heart failure (NHYA class III or IV), treatment with glucocorticoid at a dose over or equal to 0.5mg/kg/d for 15 days or more at time of inclusion or during the previous 6 months; thyroid or other endocrine disease if untreated for more than 6 months; hypercalciuria Testosterone below normal if treatment is hormonal BMI below or equal to 18 Severe lung failure Chronic alcohol intoxication Ongoing opportunistic infection Gastric ulcer of disease interfering with oesophageal motility in the previous 3 months History of treatment for osteoporosis History of malignancy in the previous 5 years (except skin cancer and Kaposi) Cytotoxic chemotherapy or cytokine therapy Liver cirrhosis Breast feeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>Osteoporosis</keyword>
</DOC>